

Searching for therapeutic synergy in primary effusion lymphoma

May 1 2013

Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with HIV and the elderly. Because current treatment options are not effective, there is a great need for new PEL therapies.

In this issue of the *Journal of Clinical Investigation*, Juan Carlos Ramos and colleagues at the University of Miami used an immunocompromised mouse model of PEL to determine the efficacy of Bortezomib/Vorinostat combination therapy, two drugs that are currently being used to treat [multiple myeloma](#) and cutaneous [T cell lymphoma](#), respectively. They found that this treatment combination reactivated virus-induced cell lysis and induced PEL cell death, increasing the lifespan of mice with PEL tumors.

These findings indicate that this drug combination could potentially be beneficial in immunocompromised patients with KSHV-associated malignancies.

More information: Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma, *J Clin Invest.* [doi:10.1172/JCI64503](https://doi.org/10.1172/JCI64503)

Provided by Journal of Clinical Investigation

Citation: Searching for therapeutic synergy in primary effusion lymphoma (2013, May 1)
retrieved 20 March 2024 from <https://medicalxpress.com/news/2013-05-therapeutic-synergy-primary-effusion-lymphoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.